Handelsbanken Fonder AB Sells 47,932 Shares of Illumina, Inc. $ILMN

Handelsbanken Fonder AB lowered its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 54.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 40,400 shares of the life sciences company's stock after selling 47,932 shares during the period. Handelsbanken Fonder AB's holdings in Illumina were worth $3,855,000 at the end of the most recent quarter.

• GRAIL: Biotech Stock Targeting $100B Cancer Market

A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. Corvex Management LP grew its position in shares of Illumina by 125.2% during the first quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company's stock valued at $303,841,000 after purchasing an additional 2,129,449 shares in the last quarter. AQR Capital Management LLC grew its holdings in Illumina by 361.7% during the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company's stock valued at $165,484,000 after buying an additional 1,662,093 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Illumina by 11,714.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,161,882 shares of the life sciences company's stock worth $92,184,000 after acquiring an additional 1,152,048 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Illumina by 51.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company's stock worth $155,537,000 after acquiring an additional 667,978 shares in the last quarter. Finally, PGGM Investments raised its holdings in shares of Illumina by 115.1% during the 2nd quarter. PGGM Investments now owns 1,149,408 shares of the life sciences company's stock worth $109,665,000 after acquiring an additional 614,973 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ILMN shares. Weiss Ratings restated a "sell (d+)" rating on shares of Illumina in a report on Wednesday, October 8th. Barclays boosted their price objective on Illumina from $95.00 to $100.00 and gave the stock an "underweight" rating in a research note on Friday, October 31st. Daiwa Capital Markets lowered Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective for the company. in a research note on Tuesday, August 12th. UBS Group lifted their target price on Illumina from $110.00 to $120.00 and gave the stock a "neutral" rating in a report on Friday, October 31st. Finally, Cowen reissued a "hold" rating on shares of Illumina in a research report on Friday, October 31st. Five research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $115.00.

• Strategic Buy Lights Up This Biotech Stock: Time to Invest?

View Our Latest Report on Illumina

Illumina Trading Up 1.7%

Shares of NASDAQ ILMN opened at $125.96 on Tuesday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $153.06. The firm has a market cap of $19.25 billion, a PE ratio of 15.94, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The business has a fifty day simple moving average of $105.72 and a two-hundred day simple moving average of $98.01. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66.

• Palantir Was Left Out of the S&P 500; It Still Looks Like a Buy

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion during the quarter, compared to analysts' expectations of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company's revenue was up .4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, Director Scott Gottlieb acquired 500 shares of the firm's stock in a transaction on Monday, November 3rd. The stock was acquired at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the purchase, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.60% of the company's stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Read More

• Five stocks we like better than Illumina
• How to trade using analyst ratings
• D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?
• How to Choose Top Rated Stocks
• Hims, Block, and NRG Just Launched Huge Stock Buybacks
• What is diluted earnings per share (Diluted EPS)?
• Retail Earnings Roundup: Walmart Scores, Target Slumps in Q3

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Illumina Right Now?

Before you consider Illumina, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.

While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here